Gene Editing: How much justice delayed or denied?
By Nicholas G. Evans,
Impact Ethics
| 12. 02. 2015
The International Summit on Human Gene Editing: A Global Discussion is a three-day event convened by the Chinese Academy of Sciences, The Royal Society, the United States (US) National Academy of Sciences, and US National Academy of Medicine. The Summit has a live webcast, a vibrant Twitter hashtag, and is being reported by major news organizations and blogs alike.
I want to pick up on one very small piece of this immense puzzle, highlighted by philosopher John Harris in the penultimate session of day one of the Summit (you can find his talk here). Harris, at the University of Manchester, highlighted three allegedly “obviously fallacious and dogmatic” arguments against the editing of the human genome:
- Arguments from the sacredness of the human genome;
- Arguments from the “unacceptable risks to future generations” as a result of human gene editing;
- The inability to get consent from children produced as a result of human gene editing.
I want to pick up the second of these, and concentrate solely on the question of editing the human genome in embryos, which is Harris’ main talking...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...